Literature DB >> 31862655

Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: A case report.

Fereshteh Ashtari1, Mohammad Ali Sahraian2, Marjan Oustad3, Yalda Nilipour4.   

Abstract

Rebound syndrome can occur as a flare-up disease activity after stopping treatment in multiple sclerosis (MS). A potential rebound activity has recently been reported after fingolimod cessation with increasing clinical and radiographic activity, which makes decision-making about the discontinuation of treatment a major concern. This article reports on a patient with tumefactive rebound of MS who presented with acute onset encephalopathy and progressive motor deficiencies a few days after fingolimod cessation. Despite the invasive treatment, the disease progressed and resulted in the patient's death. This article discusses the clinical course of the disease and the MRI findings and compares them with the findings of previous reports. The present case shows that rebound activity can occur even after a short-term fingolimod withdrawal and may present with acute onset encephalopathy and aphasia.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fingolimod; Multiple sclerosis; Rebound

Year:  2019        PMID: 31862655     DOI: 10.1016/j.msard.2019.101883

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  2 in total

Review 1.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

2.  Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod.

Authors:  Kensuke Senzaki; Hirofumi Ochi; Masayuki Ochi; Yoko Okada; Shiroh Miura; Yasumasa Ohyagi
Journal:  eNeurologicalSci       Date:  2021-05-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.